samedan logo

 
 
spacer
home > advertise
ADVERTISING OPPORTUNITIES
Why Advertise with Samedan?

 

Samedan's range of specialist titles spans the full spectrum of pharmaceutical development, from innovation to patient, and is designed to meet the broad
needs of an industry built on high-quality information, communication, and expertise.

With a history going back more than a decade, Samedan's clients range from long-established industry leaders to the most recent start-ups and university spin-outs.
Many clients have advertised across our entire range for years and have come to
appreciate a strong and cooperative relationship with us.

Samedan is committed to providing the perfect editorial platform for your advert.
That is why our featured articles take an opinion-led, non-promotional view of the industry. This ensures that every advert enjoys maximum impact with each title's readership of 10,000+ key decision makers.

For further information about each of our titles, follow the links below. Each of our advertising executives can be contacted at the email addresses below and will be
pleased to discuss how Samedan can meet your needs.

Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

European Pharmaceutical Contractor
Simon Caplan: simon@samedanltd.com

European BioPharmaceutical Review
Helga Schweissguth: helga@samedanltd.com

International Clinical Trials
Simon Caplan: simon@samedanltd.com

Pharmaceutical Manufacturing and Packing Sourcer
Simon Caplan: simon@samedanltd.com

Innovations in Pharmaceutical Technology
Helga Schweissguth: helga@samedanltd.com



 

spacer

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

News and Press Releases

Peptilogics Closes $35.4 Million Series B Financing to Further Advance Proprietary Computational Peptide Drug Design and Discovery Platform

PITTSBURGH, PA, Dec. 21, 2020 /PRNewswire/ -- Peptilogics announced today the closing of a $35.4 million Series B financing. The financing was led by Presight Capital, with participation from a new investor syndicate including Founders Fund as well as from existing investor Peter Thiel. The proceeds of the financing will be used to expand Peptilogics’ computational platform and invest in technologies to improve its drug design engine, as well as accelerate development of a pipeline of peptide therapeutics including the Company’s lead clinical asset, PLG0206, which has demonstrated first-in-class safety and best-in-class efficacy.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement